Scancell (LON:SCLP) Shares Up 7% After Insider Buying Activity

Scancell Holdings plc (LON:SCLP - Get Free Report) traded up 7% during mid-day trading on Thursday following insider buying activity. The company traded as high as GBX 10.43 ($0.14) and last traded at GBX 9.90 ($0.13). 1,065,551 shares traded hands during mid-day trading, an increase of 21% from the average session volume of 878,498 shares. The stock had previously closed at GBX 9.25 ($0.13).

Specifically, insider Martin Diggle purchased 44,944 shares of Scancell stock in a transaction that occurred on Tuesday, May 20th. The stock was acquired at an average price of GBX 9 ($0.12) per share, for a total transaction of £4,044.96 ($5,475.78).

Scancell Price Performance

The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The firm has a market cap of £102.54 million, a P/E ratio of -15.18 and a beta of 0.35. The business has a fifty day moving average of GBX 9.41 and a 200 day moving average of GBX 10.19.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.